Clovis Oncology, Inc. (CLVS) Is At $59.15 Formed Wedge; Aetna (AET) Has 0.91 Sentiment

Aetna Inc. operates as a health care benefits firm in the United States. The company has market cap of $57.63 billion. It operates through three divisions: Health Care, Group Insurance, and Large Case Pensions. It has a 31.03 P/E ratio. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis.

Clovis Oncology, Inc. (CLVS) formed wedge down with $53.83 target or 9.00% below today’s $59.15 share price. Clovis Oncology, Inc. (CLVS) has $2.90B valuation. The stock increased 6.56% or $3.64 during the last trading session, reaching $59.15. About 3.06M shares traded or 130.90% up from the average. Clovis Oncology, Inc. (NASDAQ:CLVS) has risen 282.71% since February 28, 2017 and is uptrending. It has outperformed by 266.01% the S&P500.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology has $134 highest and $15 lowest target. $71.17’s average target is 20.32% above currents $59.15 stock price. Clovis Oncology had 59 analyst reports since September 10, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, August 24 by Suntrust Robinson. Piper Jaffray maintained the shares of CLVS in report on Monday, November 16 with “Neutral” rating. The firm has “Buy” rating by Suntrust Robinson given on Friday, September 23. The firm earned “Buy” rating on Friday, August 5 by Suntrust Robinson. Mizuho downgraded the shares of CLVS in report on Monday, November 16 to “Neutral” rating. Leerink Swann maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Wednesday, November 15 with “Buy” rating. The company was upgraded on Tuesday, December 20 by Chardan Capital Markets. On Thursday, June 1 the stock rating was maintained by J.P. Morgan with “Buy”. The stock has “Outperform” rating by RBC Capital Markets on Thursday, February 22. The firm has “Neutral” rating by Piper Jaffray given on Monday, April 4.

Since September 15, 2017, it had 0 buys, and 7 selling transactions for $1.56 million activity. The insider IVERS-READ GILLIAN C sold $208,500. 4,500 shares valued at $292,365 were sold by SPICKSCHEN THORLEF on Monday, January 8.

Investors sentiment decreased to 1.44 in Q3 2017. Its down 0.37, from 1.81 in 2017Q2. It fall, as 48 investors sold Clovis Oncology, Inc. shares while 49 reduced holdings. 42 funds opened positions while 98 raised stakes. 47.46 million shares or 2.14% more from 46.46 million shares in 2017Q2 were reported. Pictet Asset Management Ltd holds 0.09% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 367,029 shares. The Japan-based Nomura has invested 0% in Clovis Oncology, Inc. (NASDAQ:CLVS). Atwood Palmer Inc owns 100 shares. Kingdon Capital Management Ltd Llc accumulated 155,962 shares or 0.84% of the stock. Weiss Multi reported 30,000 shares or 0.09% of all its holdings. Comml Bank Of Montreal Can holds 0% or 6,083 shares in its portfolio. Cornerstone Cap Mngmt Liability Company has invested 0.01% in Clovis Oncology, Inc. (NASDAQ:CLVS). Moreover, Morgan Stanley has 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 198,903 shares. Smith Asset Mgmt Grp Inc Limited Partnership owns 8,050 shares or 0.02% of their US portfolio. Putnam Invs Ltd Llc invested in 0.16% or 827,155 shares. First Mercantile Trust reported 6,844 shares. Kazazian Asset Mngmt Ltd Llc accumulated 17,493 shares. Birchview L P has 5,000 shares for 0.21% of their portfolio. Endurant Mngmt Lp, California-based fund reported 56,750 shares. Fifth Third Commercial Bank holds 0% or 394 shares in its portfolio.

Michael & Susan Dell Foundation holds 15.62% of its portfolio in Aetna Inc. for 124,616 shares. Healthcor Management L.P. owns 1.13 million shares or 6.03% of their US portfolio. Moreover, Lyrical Asset Management Lp has 4.61% invested in the company for 2.22 million shares. The California-based Focused Investors Llc has invested 4.56% in the stock. Sio Capital Management Llc, a New York-based fund reported 50,523 shares.

Ratings analysis reveals 20% of Aetna’s analysts are positive. Out of 5 Wall Street analysts rating Aetna, 1 give it “Buy”, 0 “Sell” rating, while 4 recommend “Hold”. AET was included in 5 notes of analysts from November 11, 2016. Bernstein downgraded the shares of AET in report on Monday, November 14 to “Mkt Perform” rating. The company was downgraded on Tuesday, January 24 by Leerink Swann. The stock has “Neutral” rating by Piper Jaffray on Wednesday, January 4. Deutsche Bank initiated the shares of AET in report on Wednesday, April 5 with “Hold” rating. The stock has “Outperform” rating by Credit Suisse on Friday, November 11.

Since January 1, 0001, it had 0 insider buys, and 2 selling transactions for $4.15 million activity.

The stock increased 0.30% or $0.52 during the last trading session, reaching $176.27. About 1.23M shares traded. Aetna Inc. (AET) has risen 28.84% since February 28, 2017 and is uptrending. It has outperformed by 12.14% the S&P500.